Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VTGN with free AI briefings, catalyst countdowns, and dilution alerts.

VTGN · Vistagen Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$20M Cash on Hand
4.5mo Cash Runway
Follow VTGN by email Get an email when VTGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VTGN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Fasedienol Nasal Spray Social Anxiety Disorder (SAD) Phase 3 · NCT06615557 Completed
PH94B Social Anxiety Disorder Phase 3 · NCT05030350 Terminated
PH94B Nasal Spray Social Anxiety Disorder Phase 3 · NCT05011396 Terminated
L-4-chlorokynurenine Parkinson Disease Phase 2 · NCT04147949 Unknown
Fasedienol Nasal Spray - Fasedienol Nasal Spray Social Anxiety Disorder Phase 2 · NCT06809179 Completed
Probenecid Drug Drug Interaction Phase 1 · NCT05280054 Unknown

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VTGN holds $20M in cash and short-term investments (as of Sep 30, 2026) and burns about $13.4M/quarter from operations, an estimated runway of 4.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 87 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VTGN files for a raise →

👥 Who Owns VTGN

Insiders 0.4% Other 5%+ holders 6.4% Institutions (57 holders) 32.7% Public and other holders 60.5%
HolderTypeShares% of sharesAs of
Commodore Capital LP Institution (13G, 5%+) 4,244,590 9.19% 2026-06-30
Chen Yu 5%+ holder (13G) 2,960,404 6.41% 2026-06-30
Shawn Singh
President and CEO, Director · +375,000 options
Insider 75,721 0.16% 2026-06-30
Reid G. Adler
Chief Legal Officer · +175,000 options
Insider 60,868 0.13% 2026-06-30
Joshua S. Prince
Chief Operating Officer · +175,000 options
Insider 15,249 0.03% 2025-12-31
Cynthia Lynn Anderson
CHIEF FINANCIAL OFFICER · +100,000 options
Insider 12,801 0.03% 2025-06-30
Nick B. Tressler
Chief Financial Officer · +225,000 options
Insider 11,712 0.03% 2026-06-30

Share count 46,186,049 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VTGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VTGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.